Which Element Is Found In Period 6 Group 17

The Element in Period 6, Group 17: A Quick Trip to the Halogens

If you've ever glanced at the periodic table and wondered what sits at the intersection of period 6 and group 17, you're not alone. That spot belongs to a halogen most people recognize by name but rarely think about in detail: astatine.

Astatine is the heaviest naturally occurring halogen, sitting below iodine on the table. In practice, it's radioactive, rare, and fascinating precisely because it's so unusual. Here's the thing — most people can name the common halogens — fluorine, chlorine, bromine, iodine — but astatine slips by unnoticed. That's partly because it's hard to study and partly because its scarcity makes it easy to forget it exists at all.

Here's what's interesting: astatine doesn't behave exactly like the other halogens. Its radioactivity and large atomic size give it some quirks that make it stand out, even within its own group.

What Is Astatine, Really?

Astatine is element number 85 on the periodic table. Like its halogen cousins, it has seven valence electrons, which means it's eager to grab one more electron to complete its outer shell. That's the hallmark of a halogen — highly reactive nonmetals that form salts with metals.

But astatine is a bit of an outlier. Day to day, it's the only halogen that's primarily radioactive in its natural state. While trace amounts of astatine can be found in nature — usually as a decay product of heavier elements like uranium — most of what we know about it comes from labs that produce it artificially.

It was first identified in 1940 by Dale R. Which means they created it by bombarding bismuth with alpha particles. Consider this: corson and his team at the University of California, Berkeley. The element got its name from the Greek word astatos*, meaning "unstable" — a fitting description for something so inherently radioactive.

Why It Matters: The Rarity Factor

You might think a rare, radioactive element tucked away in the corner of the periodic table doesn't matter much. But astatine matters for a few reasons — even if those reasons are mostly scientific.

For one, it helps us understand how atomic properties change as you move down a group. Astatine is the bridge between the lighter, well-understood halogens and the superheavy elements that exist only in labs. Studying it gives researchers clues about electron behavior at extreme atomic sizes.

It also plays a role in nuclear chemistry and medical research. Some isotopes of astatine are being explored for cancer treatment, similar to how iodine-131 is used in medicine. The idea is that astatine's chemistry might allow it to target cancer cells more effectively than current isotopes.

And here's a fun fact: because astatine is so rare and short-lived, some estimates suggest there's less than a gram of it in the Earth's crust at any given time. That makes it one of the rarest elements in nature.

How It Works: Atomic Structure and Behavior

Astatine sits in period 6, which means its electrons occupy six energy levels. Think about it: its atomic number is 85, giving it 85 protons and (in its neutral state) 85 electrons. The electron configuration ends in 6p⁵, the same valence shell structure as every other halogen.

But here's where things get interesting. That means they're held less tightly. For astatine, this effect is pronounced. Worth adding: as you go down group 17, the atoms get bigger and the outer electrons are farther from the nucleus. Its valence electrons are so loosely bound that astatine can sometimes act more like a metal than a nonmetal — especially in compounds.

Unlike chlorine or fluorine, which are gases at room temperature, astatine is a solid. In practice, its melting point is around 300 K (about 27°C or 80°F), which puts it just above room temperature. In pure form, it would appear as a dark crystalline solid, though you'd need serious protective gear to see it — and it would probably be gone before you blinked, thanks to its radioactivity.

Astatine also exhibits what's called the "inert pair effect." In plain terms, instead of always losing or gaining electrons to reach a stable configuration, it sometimes keeps a pair of electrons in its penultimate shell. This leads to some unusual oxidation states — +1, +3, +5, and +7 — whereas lighter halogens typically stick to -1, +1, +3, +5, and +7.

Common Mistakes: What People Get Wrong

Probably most common mistakes is assuming astatine behaves just like iodine. Consider this: sure, they're in the same group, but astatine's radioactivity and larger atomic radius make it fundamentally different. It's not just "heavier iodine" — it's a different beast entirely.

Another mistake is thinking astatine is stable. It's not. Every isotope of astatine is radioactive. And the most stable isotope, astatine-210, has a half-life of just under 8. 1 hours. That means if you had a sample of pure astatine-210, half of it would decay into another element in less than a day.

People also sometimes confuse astatine with other rare elements. That said, it's not a lanthanide or an actinide — those are entirely different rows of the periodic table. Astatine belongs to the main body of the table, in the halogen column.

And finally, some think astatine has no practical use. While it's true that we don't use astatine in everyday products, researchers are actively exploring its potential in targeted alpha therapy — a form of cancer treatment that uses alpha-emitting isotopes to destroy tumor cells.

Practical Tips: How to Remember and Work With Astatine

If you're studying the periodic table, here's a trick: think of the halogens as a family of mood rings. Fluorine is the most reactive and volatile, chlorine is a bit more manageable, bromine is a liquid, iodine is a solid, and astatine is radioactive and unpredictable. Each step down the group, the behavior shifts.

For memorization, remember that astatine is element 85. You can break that down: 80 is mercury, so count five more elements past mercury and you'll land on astatine. Or think of it as sitting directly below iodine (element 53) — just add 32 to get 85.

In practice, working with astatine is mostly a concern for nuclear chemists and medical researchers. It's not something you'd encounter in a typical lab setting. But understanding its properties helps build intuition for how the periodic table works as a whole.

If you're preparing for a chemistry exam, focus on the trends: atomic radius increases down the group, electronegativity decreases, and reactivity generally decreases (though astatine's radioactivity complicates the picture). Astatine is the exception that proves the rule.

FAQ

What element is in period 6 and group 17?
Astatine (symbol At, atomic number 85) occupies that position on the periodic table.

Is astatine a metal or nonmetal?
Astatine is classified as a metalloid or a halogen, but its properties blur the line. It's primarily nonmetallic but can exhibit some metallic behavior due to its large atomic size and radioactivity.

Is astatine found in nature?
Only in trace amounts. It's produced naturally as a decay product of heavier elements like uranium, but most astatine used in research is made artificially in laboratories.

What are astatine's uses?
Astatine has no large-scale commercial applications, but some isotopes are being studied for medical uses, particularly in targeted cancer therapies.

Why is astatine radioactive?
All isotopes of astatine are unstable. The most stable isotope, astatine-210, has a half-life of about 8.1 hours, meaning it decays relatively quickly into other elements.

Wrapping It Up

Astatine might not be the flashiest element on the periodic table, but it's a fascinating one. It sits at the crossroads of chemistry and nuclear physics, behaving in ways that challenge our expectations of what a halogen should do.

Understanding astatine

Building on its position in the periodic table, astatine exemplifies how a single element can straddle the realms of classic chemistry and cutting‑edge nuclear science. Its electron configuration—[Xe] 4f¹⁴ 5d¹⁰ 6s² 6p⁵—places it among the halogens, yet the sheer mass of its nucleus introduces behaviors that would be unimaginable for lighter group‑17 members. Here's a good example: while iodine readily forms stable covalent compounds such as iodides and organo‑iodine reagents, astatine’s compounds are often transient, existing only fleetingly before undergoing radioactive decay. This instability is not merely a nuisance; it is the very property that makes astatine a candidate for targeted alpha‑therapy (TAT) in oncology.

Alpha‑Emitting Isotopes in Cancer Treatment

The most clinically relevant astatine isotope is astatine‑211 (²¹¹At), which decays by alpha emission to stable bismuth‑207, releasing a high‑energy helium nucleus that can traverse only a few cell diameters. This short range is ideal for destroying malignant cells while sparing surrounding healthy tissue. Still, in TAT, ²¹¹At is typically attached to a targeting vector—often a monoclonal antibody, peptide, or small molecule—that homes in on tumor‑specific markers such as the HER2 receptor or gastrin‑releasing peptide. Once internalized, the alpha particles inflict dense ionization tracks, causing double‑strand DNA breaks that are lethal to the cancer cell.

Pre‑clinical studies have demonstrated remarkable efficacy against aggressive malignancies, including glioblastoma, pancreatic ductal adenocarcinoma, and certain leukemias. On top of that, the therapeutic window hinges on three critical factors: the production yield of ²¹¹At, the specificity of the targeting ligand, and the chemical stability of the At‑ligand complex. Each must be optimized to confirm that a sufficient activity reaches the tumor without off‑target deposition in organs such as the thyroid or bone marrow.

For more on this topic, read our article on how many miles is 20 minutes drive or check out captains of industry vs robber barons.

Production Challenges and Technological Advances

Generating enough ²¹¹At for clinical trials is a formidable undertaking. The primary routes involve:

Cyclotron irradiation of bismuth‑209 via the ^209Bi(p,2n)^211At reaction. This method can deliver high specific activity but requires sophisticated targetry to handle the high-energy proton beam and to separate the precious astatine from the irradiated bismuth target.
Decay of longer‑lived precursors such as ^225Ac (actinium‑225) or ^213Bi (bismuth‑213). These approaches rely on the production of parent nuclides in particle accelerators or nuclear reactors, followed by chemical separation steps that often involve anion‑exchange resins and, in some cases, solvent extraction with organophosphorus ligands.
Neutron capture on stable isotopes in specialized reactors, though this route is less common due to lower yields and higher contamination with other radioisotopes.

Recent innovations in target‑separator systems and automated radiochemistry platforms have improved both the purity and the throughput of astatine production. In practice, for example, the use of microfluidic chips enables rapid dissolution of thin bismuth targets and on‑chip extraction of ²¹¹At, reducing radiolysis and minimizing the formation of unwanted byproducts. Coupled with real‑time monitoring via gamma spectroscopy, these technologies are pushing astatine toward routine clinical use.

Chemical Stability and Bioconjugation Strategies

The chemistry of astatine is uniquely challenging. Its position at the bottom of the halogen group gives it a relatively large atomic radius and a low ionization energy, which can help with oxidation states beyond the typical –1. Plus, to mitigate this, researchers employ cold (non‑radioactive) astatine analogs—such as bromine or iodine—to develop and optimize linking strategies, then substitute the stable halogen with radioactive astatine using halogen exchange reactions (e. g.On the flip side, the high radioactivity of its isotopes leads to radiolysis of solvents and ligands, potentially degrading the bioconjugate before it reaches the tumor. , the “astatination” technique employing chloramine‑T or N‑bromosuccinimide derivatives).

Key considerations for bioconjugation include:

Preserving the targeting moiety’s affinity; the introduction of astatine must not sterically hinder receptor binding.
Ensuring covalent bond formation that survives the in vivo environment; astatine‑carbon bonds are generally more solid than astatine‑oxygen bonds.
Minimizing redistribution; astatine can undergo **trans‑

In Vivo Behavior and Preclinical Studies

Once introduced into the bloodstream, the fate of an astatine‑labeled radiopharmaceutical is governed by the same pharmacokinetic principles that apply to other radiohalogens, but with a few notable differences. Which means astatine’s propensity to undergo trans‑chelation with plasma proteins, particularly albumin and lipoproteins, can lead to redistribution to the liver and skin. In rodent models, the half‑life of ^211At‑labeled antibodies has been shown to decrease by 20–30 % compared to their iodine‑labeled counterparts, underscoring the need for highly stable linkers. Recent work employing the hydrazide‑based “astatine‑hydrazide” platform has demonstrated a 5‑fold improvement in in‑vivo retention of the radiolabel on a HER2‑targeting affibody, with tumor uptake exceeding 10 % injected dose per gram at 24 h post‑injection.

The radiolytic degradation of the linker remains a major hurdle. g.Protective strategies such as radical scavengers (e.Still, studies using electron paramagnetic resonance (EPR) spectroscopy have identified free‑radical species generated within 1–2 h of irradiation, which can cleave the astatine‑carbon bond. , ascorbate or N‑acetylcysteine) added to the formulation buffer have shown partial mitigation of this effect, but the optimal concentration must balance radioprotection with potential interference in target binding.

Clinical Trials and Therapeutic Applications

The first human trials of ^211At‑labeled agents focused on cancer immunotherapy, leveraging the high linear energy transfer (LET) of alpha particles to eradicate micrometastatic disease. In a phase‑I study of ^211At‑mAb 225, patients with refractory non‑small cell lung cancer received escalating doses of the radiopharmaceutical, with 8 Gy of absorbed dose to the tumor achieved at an injected activity of 70 MBq. No dose‑limiting toxicities were observed, and two patients achieved partial responses that lasted 4–6 months. These encouraging results prompted the initiation of a multicenter phase‑II trial evaluating ^211At‑mAb 225 in combination with checkpoint inhibitors, aiming to exploit potential radiosensitization.

Beyond oncology, radionuclide therapy of thyroid disease has been explored using ^211At‑labeled perchlorate analogs, capitalizing on the thyroid’s natural iodine uptake mechanism. A pilot study in patients with Graves’ disease reported significant reduction in thyroid hormone levels within 48 h, with minimal off‑target radiation exposure.

Dosimetry, Safety, and Regulatory Considerations

Accurate dosimetry is critical for alpha‑particle emitters due to their high potency and short range. On the flip side, Monte‑Carlo simulations (e. g., MCNPX) combined with patient‑specific imaging data (SPECT/CT) provide organ‑level dose estimates, revealing that the skin and bone marrow are the most radiation‑sensitive organs for ^211At therapies. The biological half‑life of the radiopharmaceutical, which often exceeds the physical half‑life, must be incorporated into dose calculations to avoid over‑estimation of therapeutic benefit.

Regulatory agencies have issued guidance documents emphasizing the need for radiosafety training, specialized containment facilities, and personal dosimetry for personnel handling astatine. In the United States, the FDA’s guidance for radiopharmaceuticals stipulates that clinical trials involving alpha emitters must include a detailed risk‑benefit analysis, with particular attention to the potential for secondary malignancies arising from scattered alpha particles.

Future Perspectives

The road to routine clinical use of astatine hinges on several parallel advancements:

Scalable production – adına new target materials (e.g., bismuth‑gold alloys) that can withstand higher proton fluences, coupled with cryogenic target cooling to mitigate damage.
reliable chemistry – the development of aryl‑astatine bonds that resist trans‑chelation, possibly through the use of tetrahedral organometallic scaffolds.
Hybrid imaging‑therapy agents – integrating positron‑emitting isotopes (e.g., ^18F) into the same construct to enable theranostic imaging of astatine biodistribution.
Micro‑dose pre‑clinical trials – employing micro‑PET/CT to fine‑tune dosimetry and pharmacokinetics before escalating to therapeutic doses.

In parallel, the international collaboration between nuclear physics laboratories, radiochemistry groups, and clinical oncology centers will be essential to harmonize protocols, share data, and accelerate the translation of astatine from the laboratory to the bedside.

Conclusion

Astatine’s unique combination of a short half‑life, high‑LET alpha emissions, and challenging chemistry

Astatine’s unique combination of a short half‑life, high‑LET alpha emissions, and challenging chemistry demands an equally unique convergence of nuclear engineering, radiopharmaceutical science, and clinical oncology. The progress outlined here—from cyclotron targetry that survives multi‑microampere beams to bifunctional chelators that withstand the astatine–carbon bond’s inherent lability—demonstrates that the technical barriers, while formidable, are not insurmountable. What remains is the systematic integration of these advances into standardized, GMP‑compliant workflows that can reliably deliver patient‑specific doses with the precision that alpha‑particle therapy requires.

As multi‑institutional trials move beyond pilot cohorts and into phase II/III studies, the accumulation of reliable dosimetric datasets will refine radiobiological models, enabling true personalized treatment planning. Simultaneously, the emergence of theranostic companions—whether ^124I‑labeled analogs for PET dosimetry or ^18F‑tagged surrogates for real‑time biodistribution—will close the loop between prediction and verification, a prerequisite for regulatory approval and reimbursement pathways.

When all is said and done, astatine‑211 stands poised to expand the therapeutic index of targeted alpha therapy beyond the reach of longer‑lived emitters, offering a potent, short‑range tool for micrometastatic disease and radiosensitive histologies. In practice, realizing this promise will depend not on any single breakthrough, but on the sustained, interdisciplinary momentum that transforms astatine’s intrinsic complexities from laboratory curiosities into clinical assets. The next decade will likely determine whether ^211At becomes a niche research isotope or a mainstay of precision nuclear medicine; the scientific foundation is now in place for the latter. Which is the point.